| 1.0225 0.013 (1.24%) | 02-06 11:12 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.29 | 1-year : | 1.51 |
| Resists | First : | 1.11 | Second : | 1.29 |
| Pivot price | 0.92 |
|||
| Supports | First : | 0.94 | Second : | 0.85 |
| MAs | MA(5) : | 0.94 |
MA(20) : | 0.92 |
| MA(100) : | 1.15  |
MA(250) : | 1.51 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 76.1 |
D(3) : | 60.6 |
| RSI | RSI(14): 60.3 |
|||
| 52-week | High : | 3.5 | Low : | 0.81 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ACET ] has closed above the upper band by 11.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 38% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.05 - 1.06 | 1.06 - 1.06 |
| Low: | 0.85 - 0.85 | 0.85 - 0.86 |
| Close: | 1 - 1.01 | 1.01 - 1.02 |
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Thu, 06 Feb 2025
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth? - Simply Wall St
Wed, 05 Feb 2025
Revolutionary Lupus Treatment Gets FDA Fast-Track: Adicet's ADI-001 Could Transform Patient Care - StockTitan
Fri, 31 Jan 2025
Adicet's New CMO Receives 750,000 Share Options Package as Company Bolsters Leadership - StockTitan
Fri, 31 Jan 2025
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Wed, 29 Jan 2025
Gamma Delta T Cell Pioneer Adicet Bio Takes Center Stage at Elite Biotech Conference - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 82 (M) |
| Shares Float | 62 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 76.4 (%) |
| Shares Short | 3,430 (K) |
| Shares Short P.Month | 4,180 (K) |
| EPS | -1.71 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.93 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.3 % |
| Return on Equity (ttm) | -58 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -91 (M) |
| Levered Free Cash Flow | -55 (M) |
| PE Ratio | -0.6 |
| PEG Ratio | 0 |
| Price to Book value | 0.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|